Načítá se...
Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease
BACKGROUND: Ustekinumab (CNTO 1275) and briakinumab (ABT‐874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin‐12 and interleukin‐23 (IL‐12/23p40), which are involved in the pathogenesis of Crohn's disease. OBJECTIVES: The objectives of this review wer...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2016
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6464484/ https://ncbi.nlm.nih.gov/pubmed/27885650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD007572.pub3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|